secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001140361-25-019151
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics Q1 net loss $9.6M; Belapectin shows liver stiffness reduction at EASL
--------------------------------------------------------------------------------

- Net loss for Q1 2025 was $9.6M ($0.15 per share) vs $11.5M ($0.19) in Q1 2024.
- Cash and equivalents $7.4M as of March 31, 2025; additional $11M available under lines of credit; runway through August 2025.
- Belapectin 2 mg/kg showed statistically significant reduction in liver stiffness from baseline at weeks 26, 52, 78 (p<0.02).
- Proportion of patients with >30% worsening in liver stiffness: 11.7% for belapectin vs 23.9% for placebo (51% fewer, p=0.03).
- Data presented at EASL May 2025; Fast Track Designation for belapectin in MASH cirrhosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125019151/0001140361-25-019151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125019151/ef20048561_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-019151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer